FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

mington, D.C. 20549	OMB APPROVAL

OMB Number: 3235-0							
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  OBrien Christopher Flint  (Last) (First) (Middle)  NEUROCRINE BIOSCIENCES, INC.				] ] 3.	2. Issuer Name and Ticker or Trading Symbol NEUROCRINE BIOSCIENCES INC NBIX  3. Date of Earliest Transaction (Month/Day/Year) 01/10/2013						BIX (Ch	Relationship of Reporting Person(s) to Issuer Check all applicable) Director Director Difficer (give title below) Chief Medical Officer					
(Street) SAN DII		A tate)	92130 (Zip)		4. If Amendment, Date of Original Filed (Month/Day/Year)						Line	X Form filed by One Reporting Person Form filed by More than One Reporting Person					
Date				Transaction	action 2A. Deemed Execution Date,		3. Transaction	4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5)		ed (A) or tr. 3, 4 and	5. Amount of Securities Beneficially Owned Following Reported		Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Dwnership Instr. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
Derivative Conversion Date Execution Date, or Exercise (Month/Day/Year) if any			Code	ransaction of ode (Instr. Derivative		Expiration Date (Month/Day/Year)		7. Title and Amou of Securities Underlying Derivative Securit (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Ownersh Form: Direct (D) or Indirect (I) (Instr.		11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code	v	(A)		Date Exercisable	Expiration Date	Title	Amount or Number of Shares						
Stock Option <sup>(1)</sup>	\$8.65	01/10/2013		A		86,000		02/10/2013	01/10/2023	Common Stock	86,000	\$8.65	86,000		D		
Restricted Stock Unit	(2)	01/10/2013		A		14,000		(3)	(3)	Common Stock	14,000	\$0	14,000		D		

## **Explanation of Responses:**

- 1. Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on February 10, 2013, an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
- $2.\ Each\ restricted\ stock\ unit\ represents\ a\ contingent\ right\ to\ receive\ one\ share\ of\ Neurocrine\ Common\ Stock.$
- 3. The restricted stock units will vest annually at 1/4 of the units vesting on January 10, 2014, January 10, 2015, January 10, 2016 and January 10, 2017, respectively.

## Remarks:

<u>Margaret E. Valeur-Jensen, By</u> <u>Power of Attorney</u>

01/14/2013

\*\* Signature of Reporting Person D

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.